The short answer
There’s no universal “best first market” in Latin America, the right answer depends on whether you’re optimizing for speed or market size. Mexico’s COFEPRIS doesn’t require sanitary registration for supplements, just an operating notice filed 30 days in advance (source), a lighter path than Brazil. Brazil offers the largest market of the three, $4.6 billion and growing 9.5% annually, with more regulatory rigor. Colombia’s INVIMA sits in between, with risk-tiered timelines depending on product classification.
Not sure which market fits your product first?
The right sequencing depends on your formula, timeline, and risk tolerance. Get a direct comparison for your specific product across all three markets.
→ Book a Paid Consulting Session (WhatsApp)Three regulators, three different models
| Country | Regulator | Supplement pathway |
|---|---|---|
| Brazil | ANVISA | Notification or registration under RDC 843/2024, risk-tiered |
| Mexico | COFEPRIS | No sanitary registration required; 30-day advance operating notice (“aviso de funcionamiento”) |
| Colombia | INVIMA | Registro sanitario, automatic for lower risk classes, fuller review (~90 business days) for higher-risk products |
ANVISA is one of only 8 top-tier regulators in the Americas
ANVISA holds WHO/PAHO Regional Reference Authority (ARNr) status at Level IV (source), one of only 8 authorities in the Americas at this tier, alongside the US FDA, Health Canada, Argentina’s ANMAT, Colombia’s INVIMA, Mexico’s COFEPRIS, Chile’s ISP, and Cuba’s CECMED. This isn’t a bureaucratic footnote, it means a GMP certificate from ANVISA can streamline recognition in Mexico, Chile, and Argentina through direct information exchange, without requiring a separate on-site visit in some cases.
Speed vs. scale: the real trade-off
Mexico’s lighter regulatory model can mean a faster path to market for a brand prioritizing speed, since there’s no product-level sanitary registration to wait on, only the advance operating notice. Brazil offers a larger prize, the biggest market of the three by a wide margin, but with more regulatory steps and a longer runway to full compliance. Colombia sits in the middle: automatic registration for lower-risk products keeps some categories moving quickly, while higher-risk classifications face a review process closer to Brazil’s timeline.
No shortcuts between markets
There’s no automatic mutual recognition between Brazil, Mexico, and Colombia for supplement approvals (source). Each market requires its own filing, its own local representative, and its own compliance documentation. ARNr Level IV recognition helps at the margins, GMP certificate recognition between authorities, for example, but it does not replace product-level notification or registration in each country.
A practical sequencing framework
| Priority | Consider entering first if… |
|---|---|
| Speed to market | Mexico, lighter notification-only path for most supplements |
| Market size and long-term scale | Brazil, largest market, fastest-growing among major economies |
| Balanced risk and moderate speed | Colombia, automatic path exists for lower-risk product classes |
Planning a Latin America expansion sequence?
Get a market-by-market breakdown for your specific product category, so you enter first where your formula and timeline actually fit best.
→ Book a Paid Consulting Session (WhatsApp) → Email: wagner@farmacerto.comRelated Reading
The Full Brazil Market Entry Guide FDA vs ANVISA: 5 Critical Differences What Brazilian Search Behavior RevealsFrequently Asked Questions
References: COFEPRIS, “Trámites de suplementos alimenticios,” gob.mx official portal. INVIMA, “Acceso a Mercados Internacionales,” WHO/PAHO ARNr Level IV recognition. KRECE, “Exportar suplementos a LATAM: registro país por país,” regulatory comparison, 2026. Camtom, “COFEPRIS: requisitos para importar suplementos alimenticios,” 2026.
Descubra mais sobre FarmaCerto
Assine para receber nossas notícias mais recentes por e-mail.